concept

DOPAMINE

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about DOPAMINE: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

470Connections

5Hypotheses

0Analyses

50Outgoing

50Incoming

9Experiments

0Debates

No summary available yet. View on Wiki →

No AI portrait yet

💡 Concept Info

Name	DOPAMINE
Key Genes/Proteins	AKT, ALPHA-SYNUCLEIN, ALZHEIMER, AMYLOID, APOE
Related Diseases	acetylcholine, ACETYLCHOLINE, Alzheimer'S Disease, ALZHEIMER'S DISEASE

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

Dopamine Metabolism Pathway

mechanism · 1138 words

→

Pathway Diagram

graph TD
    DOPAMINE["DOPAMINE"]
    DOPAMINE -->|"involved_in"| Parkinson_s_Disease["Parkinson's Disease"]
    DOPAMINE -->|"regulates"| neuronal_uptake["neuronal uptake"]
    DOPAMINE -->|"interacts"| GDNF["GDNF"]
    DOPAMINE -->|"interacts"| Substantia_Nigra["Substantia Nigra"]
    DOPAMINE -->|"treats"| diabetic_retinal_neurodegenera["diabetic retinal neurodegeneration"]
    DOPAMINE -->|"activates"| NRF2["NRF2"]
    DOPAMINE -->|"regulates"| GPX4["GPX4"]
    DOPAMINE -->|"regulates"| BDNF["BDNF"]
    DOPAMINE -->|"expressed in"| striatum["striatum"]
    COMT["COMT"] -->|"degrades"| DOPAMINE
    Atremorine["Atremorine"] -->|"interacts"| DOPAMINE
    GDNF -->|"inhibits"| DOPAMINE
    Substantia_Nigra -->|"interacts"| DOPAMINE
    levodopa["levodopa"] -->|"converts_to"| DOPAMINE

Outgoing (114)

Target	Relation	Type	Str
Locomotion	regulates	phenotype	0.95
Reward-Based Motivation	regulates	phenotype	0.95
reward-based motivation	modulates	process	0.95
Performance Monitoring	modulates	process	0.90
Parkinson'S Disease	associated_with	disease	0.90
endocrine functions	regulates	process	0.90
Addiction	associated_with	disease	0.90
Parkinson's Disease	involved_in	disease	0.90
Schizophrenia	associated_with	disease	0.90
Dopaminergic Neuron	expressed_in	cell_type	0.85
Hyperprolactinemia	associated_with	disease	0.85
Neuronal Uptake	inhibits	process	0.85
Parkinson'S Disease	protects_against	disease	0.85
A1 Astrocytes	inhibits	cell_type	0.85
BDNF	upregulates	protein	0.85
A2 Astrocytes	promotes	cell_type	0.85
Depression in Parkinson's Disease	involved_in	phenotype	0.85
NFKB	inhibits	protein	0.85
Parkinsons Disease	associated_with	disease	0.85
NLRP3	inhibits	protein	0.85
Neuronal Uptake	mediates	process	0.85
BDNF	activates	protein	0.80
Hippocampus-Dependent Learning	involved_in	process	0.80
Hyperarousal	modulates	phenotype	0.80
NF-κB	regulates	pathway	0.75
Circadian Clock Genes	modulates	pathway	0.75
NRF2	activates	protein	0.70
GDNF	interacts_with	entity	0.70
striatum	expressed_in	brain_region	0.70
BDNF	regulates	protein	0.70
ALPHA-SYNUCLEIN	activates	protein	0.70
GPX4	regulates	protein	0.70
Substantia Nigra	interacts_with	entity	0.70
diabetic retinal neurodegeneration	treats	disease	0.70
NEUROINFLAMMATION	treats	phenotype	0.70
ALZHEIMER'S DISEASE	regulates	disease	0.70
neuronal uptake	regulates	process	0.70
LYSOSOMAL DYSFUNCTION	regulates	phenotype	0.65
LYSOSOMAL DYSFUNCTION	causes	phenotype	0.65
PARKINSON'S DISEASE	targets	disease	0.65
NEURONS	produces	cell_type	0.65
DOPAMINERGIC NEURONS	targets	cell_type	0.65
DEPRESSION	treats	disease	0.65
BDNF	causes	gene	0.65
NEURODEGENERATION	protects_against	phenotype	0.65
TAU	treats	protein	0.65
GABA	inhibits	phenotype	0.65
TH	produces	gene	0.65
TH	targets	gene	0.65
CORTEX	causes	brain_region	0.65

Incoming (356)

Source	Relation	Type	Str
PARKINSON'S DISEASE	associated_with	disease	1.00
ALZHEIMER'S DISEASE	associated_with	disease	1.00
Atremorine	upregulates	compound	0.95
BDNF	associated_with	gene	0.90
IL-6	associated_with	gene	0.90
Exercise	upregulates	process	0.90
ADHD	associated_with	disease	0.90
Atremorine	activates	drug	0.85
SDA-2026-04-01-gap-20260401-225155	involves	analysis	0.85
Circadian Clock Genes	regulates	pathway	0.85
Peganum Harmala	upregulates	drug	0.85
TNF	associated_with	gene	0.82
Atremorine	interacts_with	drug	0.80
FNDC5	upregulates	protein	0.80
GLP-1R Agonists	upregulates	drug	0.80
COMT	degrades	gene	0.80
LRRK2	associated_with	gene	0.74
AMYLOID	associated_with	protein	0.74
GDNF	activates	entity	0.70
GDNF	therapeutic_target	entity	0.70
GDNF	interacts_with	entity	0.70
GDNF	inhibits	entity	0.70
ginsenoside Rb1	regulates	drug	0.70
lipopolysaccharide	inhibits	drug	0.70
Ginsenoside Rb1	activates	drug	0.70
Substantia Nigra	interacts_with	entity	0.70
OXIDATIVE STRESS	interacts_with	phenotype	0.70
Substantia Nigra	regulates	entity	0.70
Substantia Nigra	activates	entity	0.70
PARKINSON'S DISEASE	exacerbates	disease	0.70
TH	regulates	gene	0.70
ALPHA-SYNUCLEIN	inhibits	protein	0.70
ALPHA-SYNUCLEIN	causes	protein	0.70
ALPHA-SYNUCLEIN	interacts_with	protein	0.70
PARKINSON'S DISEASE	destabilizes	disease	0.70
TH	activates	gene	0.70
CHOLESTEROL	inhibits	phenotype	0.70
DRD2	causes	gene	0.70
ASTROCYTE	protects_against	cell_type	0.70
levodopa	converts_to	drug	0.70
PARKIN	causes	gene	0.70
PARKIN	associated_with	gene	0.66
LC3	associated_with	protein	0.66
PARKINSON'S DISEASE	treats	disease	0.65
CANAGLIFLOZIN	activates	drug	0.65
TH	interacts_with	gene	0.65
TH	causes	gene	0.65
TNF	inhibits	gene	0.65
SUCCINATE	inhibits	phenotype	0.65
ROS	activates	phenotype	0.65

Targeting Hypotheses (5)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
NMN Supplementation Restores SIRT1/p66Shc/FOXO3 Epigenetic A	0.790	neurodegeneration	epigenetic reprogramming aging neurons
Dopaminergic Ventral Tegmental-Hippocampal Circuit Protectio	0.740	neuroscience	Circuit-level neural dynamics in neurode
BH4 Cofactor Restoration as Primary Driver of >500-Fold Dopa	0.618	neurodegeneration	What molecular mechanisms underlie Atrem
Correcting Gut Microbial Dopamine Imbalance to Support Syste	0.606	neurodegeneration	What are the mechanisms by which gut mic
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis	0.384	neurodegeneration	What are the mechanisms by which gut mic

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (9)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Plasma ATN biomarkers across AD continuum in Chilean cohort	clinical	Alzheimer's disease	0.950	0.00	Chilean older adults (n=318) w	proposed	N/A
Tau depletion effects on neuronal development in primary cultures	exploratory		0.900	0.00	primary rodent neuronal cultur	proposed	N/A
Differential GWAS of schizophrenia vs PTSD	exploratory	schizophrenia, post-traumatic	0.900	0.00	human patients - European ance	proposed	N/A
Tau depletion effects on neuronal development in primary cultures	exploratory		0.900	0.00	primary rodent neuronal cultur	proposed	N/A
Creation and validation of 3xAD-ChAT-Cre mouse model	validation	Alzheimer's disease	0.900	0.00	3xAD-ChAT-Cre transgenic mice	proposed	N/A
GTEx brain tissue expression analysis of MAPT/CRHR1 locus	exploratory	schizophrenia, post-traumatic	0.850	0.00	human brain tissue samples fro	proposed	N/A
Microtubule domain analysis in adult axons	exploratory		0.800	0.00	adult rodent axons	proposed	N/A
Tau depletion effects on microtubule domains in adult axons	exploratory		0.800	0.00	adult rodent neurons	proposed	N/A
Levodopa-Induced Dyskinesias Mechanism — Experiment Design	validation	Neurodegeneration	0.400	0.50	human	proposed	$2,280,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders [PMID:41699128]	["Bolsewig K", "Bellomo G", "Hok-A-Hin Y	Nature medicine	2026
Gene therapy for Parkinson's disease: current landscape, translational challenge [PMID:41837837]	Evola V, Parmar MS	Expert review of neurotherapeu	2026
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by [PMID:39881147]	["Bolsewig K", "Willemse E", "S\u00e1nch	Nature communications	2025
Neurosurgical gene therapy for central nervous system diseases. [PMID:39191071]	Patel RV, Nanda P, Richardson RM	Neurotherapeutics : the journa	2024
Characterization of Vps13b-mutant mice reveals neuroanatomical and behavioral ph [PMID:37573958]	["Montillot C", "Skutunova E", "Ayushma"	Neurobiology of disease	2023
Interplay between the catecholaminergic enzymatic axis and neurodegeneration/neu [PMID:36692274]	["Motta C", "Assogna M", "Bonomi C", "Di	European journal of neurology	2023
Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC d [PMID:34763085]	Tai CH, Lee NC, Chien YH, Byrne BJ, Mura	Molecular therapy : the journa	2022
Gene therapy restores dopamine transporter expression and ameliorates pathology [PMID:34011628]	Ng J, Barral S, De La Fuente Barrigon C,	Science translational medicine	2021
Current Clinical Applications of In Vivo Gene Therapy with AAVs. [PMID:33309881]	Mendell JR, Al-Zaidy SA, Rodino-Klapac L	Molecular therapy : the journa	2021
Targeting autophagy using small-molecule compounds to improve potential therapy [PMID:34729301]	Zhang K, Zhu S, Li J, Jiang T, Feng L, P	Acta pharmaceutica Sinica. B	2021
Bi-allelic loss of function variants in SLC30A5 as cause of perinatal lethal car [PMID:33547425]	Lieberwirth JK, Joset P, Heinze A, Hents	European journal of human gene	2021
Graphene bilayers with a twist. [PMID:33208935]	["Andrei E", "MacDonald A"]	Nature materials	2020
Reconstruction of cell spatial organization from single-cell RNA sequencing data [PMID:32541867]	["Ren X", "Zhong G", "Zhang Q", "Zhang L	Cell research	2020
Environmental Regulation, Technological Innovation, and Export Competitiveness: [PMID:32102174]	Liu J, Xie J	International journal of envir	2020
Predicting Subjective Recovery from Lower Limb Surgery Using Consumer Wearables. [PMID:33442582]	Karas M, Marinsek N, Goldhahn J, Foschin	Digital biomarkers	2020
Gene therapy for neurodegenerative disorders: advances, insights and prospects. [PMID:32963936]	Chen W, Hu Y, Ju D	Acta pharmaceutica Sinica. B	2020
Ligand entry in human ileal bile acid-binding protein is mediated by histidine p [PMID:30886237]	["Horv\u00e1th G", "Egyed O", "Tang C",	Scientific reports	2019
[Skin Changes in POEMS Syndrome]. [PMID:30988219]	["Kuwabara S"]	Brain and nerve = Shinkei kenk	2019
DOPA Decarboxylase Modulates Tau Toxicity. [PMID:28751068]	["Kow R", "Sikkema C", "Wheeler J", "Wil	Biological psychiatry	2018
Consensus guideline for the diagnosis and treatment of aromatic l-amino acid dec [PMID:28100251]	Wassenberg T, Molero-Luis M, Jeltsch K,	Orphanet journal of rare disea	2017

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity